ForexالبورصةBourseBolsa股市AktienBorsaFinansФорексFXFinançasGiełdaΧρηματιστήριοBeursBörsPörssi금융
Feb 13, 2012 04:22AM GMT
     
 
  New York   London   Tokyo 
   
 

UPDATE 1-Avapro blood pressure drug fails heart failure trial

By Reuters  |  General News  |  Nov 11, 2008 02:03PM GMT
 
 

NEW ORLEANS, Nov 11 (Reuters) - The blood pressure medicine Avapro, sold by Bristol-Myers Squibb Co and Sanofi-Aventis, was no better than usual care in treating a type of heart failure that primarily affects women and the elderly, according to results of a large study.

Researchers had hoped to show that Avapro could reduce incidence of death and serious heart problems better than medicines currently used in this patient population that only treat symptoms of the disease.

There was a small advantage with Avapro in the study's composite goal of reducing death from any cause, heart attacks, strokes and hospitalizations for heart failure, unstable angina or arrhythmia compared with usual care, but it was not statistically significant, researchers said.

"We were particularly disappointed because we still have large numbers of patients that still don't have a good treatment," said Dr. Barry Massie, who presented the data at the American Heart Association scientific meeting here on Tuesday. (Reporting by Bill Berkrot and Ransdell Pierson, editing by Dave Zimmerman)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data .

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
CFDs Quotes
 SPX 500 Futures1347.15+6.65+0.50%  
 NQ 100 Futures2561.10+12.60+0.49%  
 US 3012801.23-89.23-0.69%  
 DAX6692.96-95.84-1.41%  
 UK 1005852.39-43.08-0.73%  
 Japan 2259010.50+63.33+0.71%  
 US Dollar Index78.91-0.20-0.26%  
CFDs Quotes
 Gold1729.95+4.65+0.27%  
 Silver33.793+0.189+0.56%  
 Copper3.888+0.027+0.69%  
 Crude Oil99.92+0.89+0.90%  
 Natural Gas2.429-0.047-1.90%  
 US Cotton No.291.56+0.53+0.58%  
 US Coffee C218.60+0.00+0.00%  
 
 EUR/USD1.3245+0.0047+0.36%  
 GBP/USD1.5788+0.0032+0.20%  
 USD/JPY77.61-0.01-0.01%  
 USD/CHF0.9134-0.0031-0.34%  
 AUD/USD1.0738+0.0065+0.61%  
 USD/CAD0.9995-0.0018-0.18%  
 EUR/CHF1.2098+0.0005+0.04%  
CFDs Quotes
 Euro Bund138.66+1.41+1.03%  
 Italian Govt. B.102.45-1.63-1.57%  
 Euro BOBL125.23+0.71+0.57%  
 UK Gilt115.78+1.13+0.99%  
 US 2 YR T-Note110.26+0.00+0.00%  
 US 10 YR T-Note131.10-0.11-0.08%  
 US 30 YR T-Bond142.20-0.23-0.16%  

Recent Activity

Sponsored Links